Authors:
D. Tsetis1, A. Katsamouris1, Z. Androulakakis1, K. Chamalakis1, T. Kostas1, E. Karagiannakidis1, N. Gourtsoyiannis2; 1Iraklion/GR, 2Heraklion/GR
DOI:
10.1594/ECR03/C-0668
References
1.Swischuk JL, Fox PF, Young K, et al. Transcatheter intraarterial infusion of rt-PA for acute lower limb ischemia: results and complications J Vasc Interv Radiol 2001;12: 423-430.2.Rao AK, Pratt C, Berke A, et al. Thrombolysis in myocardial infarction (TIMI) trial-phase1: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11: 1-113.Verstraete M, Bounameaux H, De Cock, et al. Pharmacokinetics and systemic fibrinogenolytic effects of recombinant tissue-type plasminogen activator (rt-PA) in humans. J Pharmacol Exp Ther 1985 ; 235 : 506-12. 4.Braithwaite BD, Buckenham TM, Galland RB, et al. Prospective randomized trial of high-dose bolus versus low-dose tissue plasminogen activator infusion in the management of acute limb ischemia. Br J Surg 1997; 84: 646-650. 5.Rauber K, Heidinger KS, Kemkes-Matthes B. Coagulation alterations due to local fibrinolytic therapy with recombinant tissue-type plasminogen activator (rt-PA) in patients with peripheral arterial occlusive disease. Cardiovasc Intervent Radiol 1997; 20: 169-17311.6.Hall TB, Matson M, Belli AM. Thrombolysis in the peripheral vascular system. Eur Radiol 2001;11: 439-445 7.Morgan R, Belli AM. Percutaneous thrombectomy: a review. Eur Radiol. 2002; 12: 205-217